# EDGAR Filing Document

**Accession Number:** 0001579982
**File Stem:** 0000940400-25-014991
**Filing Date:** 2025-12
**Character Count:** 25267
**Document Hash:** 8feb8845d54100fdd2dd3873f4cea69c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000940400-25-014991.hdr.sgml**: 20251229

**ACCESSION NUMBER**: 0000940400-25-014991

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251031

**FILED AS OF DATE**: 20251229

**DATE AS OF CHANGE**: 20251229

**PERIOD START**: 20260731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ARK ETF Trust
- **CENTRAL INDEX KEY:** 0001579982

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0831

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-22883
- **FILM NUMBER:** 251607018

**BUSINESS ADDRESS:**
- **STREET 1:** 155 WEST 19TH STREET, FIFTH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10011
- **BUSINESS PHONE:** 212.426.7040

**MAIL ADDRESS:**
- **STREET 1:** 155 WEST 19TH STREET, FIFTH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10011

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ark ETF Trust
- **DATE OF NAME CHANGE:** 20130624

## Series and Classes Contracts Data

### ARK Genomic Revolution ETF (Series ID: S000042975)

| Class ID   | Class Name                 | Ticker Symbol   |
|:---|:---|:---|
| C000133119 | ARK Genomic Revolution ETF | ARKG            |

## Nport-Ex

Schedule of Investments

ARK Genomic Revolution ETF

October 31, 2025 (Unaudited)

---

| | | |
|:---|:---|:---|
| **Investments** | **Shares** | **Value** |
| **COMMON STOCKS–99.8%** | | |
| **Biotechnology - 54.9%** | | |
| Absci Corp.\*<sup>†</sup> | 11652929 | $49874536 |
| Amgen, Inc. | 48114 | 14358661 |
| Arcturus Therapeutics Holdings, Inc.\*<sup>†</sup> | 2451103 | 24437497 |
| Beam Therapeutics, Inc.\* | 1977658 | 49461227 |
| CareDx, Inc.\* | 2139462 | 32091930 |
| Caris Life Sciences, Inc.\* | 247983 | 7459329 |
| Compass Pathways PLC (United Kingdom)\*<sup>(a)</sup> | 2157864 | 13637700 |
| CRISPR Therapeutics AG (Switzerland)\* | 1793364 | 114757362 |
| Exact Sciences Corp.\* | 340042 | 21997317 |
| Incyte Corp.\* | 149878 | 14010595 |
| Intellia Therapeutics, Inc.\* | 3095606 | 39066548 |
| Ionis Pharmaceuticals, Inc.\* | 614488 | 45656458 |
| Natera, Inc.\* | 278278 | 55357842 |
| Nurix Therapeutics, Inc.\* | 1535169 | 19865087 |
| Prime Medicine, Inc.\* | 5015204 | 24775108 |
| Recursion Pharmaceuticals, Inc., Class A\* | 11438284 | 63139328 |
| Regeneron Pharmaceuticals, Inc. | 12260 | 7991068 |
| Twist Bioscience Corp.\* | 2107045 | 69300710 |
| Veracyte, Inc.\* | 1132313 | 40853853 |
| Vertex Pharmaceuticals, Inc.\* | 26103 | 11108654 |
| &nbsp;&nbsp;&nbsp;Total Biotechnology |  | 719200810 |
| **Electronic Equipment, Instruments & Components - 1.2%** | **Electronic Equipment, Instruments & Components - 1.2%** | **Electronic Equipment, Instruments & Components - 1.2%** |
| 908 Devices, Inc.\*<sup>†</sup> | 1987967 | 15863977 |
| **Health Care Equipment & Supplies - 2.1%** |  |  |
| Butterfly Network, Inc.\* | 6266402 | 16856622 |
| Cerus Corp.\* | 6731213 | 9894883 |
| &nbsp;&nbsp;&nbsp;Total Health Care Equipment & Supplies |  | 26751505 |
| **Health Care Providers & Services - 6.0%** |  |  |
| GeneDx Holdings Corp.\* | 104522 | 14310107 |
| Guardant Health, Inc.\* | 693573 | 64516161 |
| &nbsp;&nbsp;&nbsp;Total Health Care Providers & Services |  | 78826268 |
| **Health Care Technology - 4.0%** |  |  |
| Schrodinger, Inc.\* | 1916963 | 40332901 |
| Veeva Systems, Inc., Class A\* | 41188 | 11993946 |
| &nbsp;&nbsp;&nbsp;Total Health Care Technology |  | 52326847 |
| **Life Sciences Tools & Services - 30.2%** |  |  |
| 10X Genomics, Inc., Class A\* | 3273458 | 44649967 |
| Adaptive Biotechnologies Corp.\* | 2823807 | 49021289 |
| Illumina, Inc.\* | 393513 | 48614596 |
| Pacific Biosciences of California, Inc.\* | 10912676 | 25535662 |
| Personalis, Inc.\*<sup>†</sup> | 7932773 | 76471932 |
| Quantum-Si, Inc.\* | 7053998 | 15166096 |
| Standard BioTools, Inc.\* | 3081891 | 3698269 |
| Tempus AI, Inc.\* | 1485368 | 133460315 |
| &nbsp;&nbsp;&nbsp;Total Life Sciences Tools & Services |  | 396618126 |
| **Pharmaceuticals - 1.4%** |  |  |
| ATAI Life Sciences NV (Germany)\* | 3040124 | 17754324 |
| **Total Common Stocks** |  |  |
| &nbsp;&nbsp;&nbsp;(Cost $2,626,578,993) |  | 1307341857 |
| **MONEY MARKET FUND–0.0%<sup>(b)</sup>**<br> Goldman Sachs Financial Square Treasury<br>|  |  |
| &nbsp;&nbsp;&nbsp;Obligations Fund, 3.94% <sup>(c)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;(Cost $585,096) | 585096 | 585096 |
| **Total Investments–99.8%** |  |  |
| &nbsp;&nbsp;&nbsp;(Cost $2,627,164,089) |  | **1307926953** |
| Other Assets in Excess of Liabilities–0.2% |  | 3174714 |
| **Net Assets–100.0%** |  | $**1311101667** |

---

---

| | |
|:---|:---|
| † | Affiliated security |
| \* | Non-income producing security |
| (a) | American Depositary Receipt |
| (b) | Less than 0.05% |
| (c) | Rate shown represents annualized 7-day yield as of October 31, 2025. |

---

Schedule of Investments (continued)

ARK Genomic Revolution ETF

October 31, 2025 (Unaudited)

**Affiliated Issuer Transactions**

An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities, or a company that is under common ownership or control. Period-to-date transactions with companies which are or were affiliates are as follows:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Value ($) at<br> 7/31/2025<sup>(a)</sup>** | **Purchases<br> Cost ($)** | **Sales<br> Proceeds ($)** | **Net Realized<br> Gain/(Loss) on<br> investments in<br> affiliated<br> securities ($)** | **Net Change in<br> Unrealized<br> Appreciation<br> (Depreciation)<br> on investments<br> in affiliated<br> securities ($)** | **Net Change in<br> Unrealized<br> Appreciation<br> (Depreciation)<br> on investments<br> in non-affiliated<br> securities ($)** | **Affiliated<br> Dividend<br> Income<br> ($)** | **Capital Gain<br> Distributions<br> ($)** | **Number of<br> Shares at<br> 10/31/2025** | **Value ($) at<br> 10/31/2025<sup>(a)</sup>** |
| **Common Stocks — 12.7%** | **Common Stocks — 12.7%** |  |  |  |  |  |  |  |  |
| Biotechnology — 5.7% | Biotechnology — 5.7% |  |  |  |  |  |  |  |  |
| Absci Corp. |  |  |  |  |  |  |  |  |  |
| 33212741 | 14227255 | (12991473) | 1686396 | 13739617 |  |  |  | 11652929 | 49874536 |
| Arcturus Therapeutics Holdings, Inc. | Arcturus Therapeutics Holdings, Inc. | Arcturus Therapeutics Holdings, Inc. |  |  |  |  |  |  |  |
| 20607391 | 21353238 | (10432974) | 314117 | (7404275) |  |  |  | 2451103 | 24437497 |
| Electronic Equipment, Instruments & Components — 1.2% <br> 908 Devices, Inc. | Electronic Equipment, Instruments & Components — 1.2% <br> 908 Devices, Inc. | Electronic Equipment, Instruments & Components — 1.2% <br> 908 Devices, Inc. | Electronic Equipment, Instruments & Components — 1.2% <br> 908 Devices, Inc. | Electronic Equipment, Instruments & Components — 1.2% <br> 908 Devices, Inc. |  |  |  |  |  |
| 14371630 | 5126591 | (6163170) | (8517631) | 11046557 |  |  |  | 1987967 | 15863977 |
| Life Sciences Tools & Services — 5.8% | Life Sciences Tools & Services — 5.8% | Life Sciences Tools & Services — 5.8% | Life Sciences Tools & Services — 5.8% |  |  |  |  |  |  |
| Personalis, Inc. | Personalis, Inc. |  |  |  |  |  |  |  |  |
| 38378556 | 25218064 | (19979847) | (83772) | 32938931 | – | – | – | 7932773 | 76471932 |
| $106570318 | $65925148 | $(49567464) | $(6600890) | $50320830 | $– | $– | $– | 24024772 | $&nbsp;&nbsp;&nbsp;&nbsp;166647942 |

---

(a) The fair value and number of shares of
 securities are only displayed at the beginning and end of each reporting period when such securities
 were considered an affiliate as of each date. Refer to the Schedule of Investments for view the fair
 value and number of shares as of October 31, 2025.

**Fair Value Measurement**

The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (i) market participant assumptions developed based on market data obtained from sources independent of the Fund (observable inputs) and (ii) the Fund's own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:

• **Level 1** — Quoted prices in active markets for identical assets.

• **Level 2** — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).

• **Level 3** — Significant unobservable inputs (including each Fund's own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the valuations as of October 31, 2025, based upon the three levels defined above:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **ARK Genomic Revolution ETF** | **Level 1** | **Level 2** | **Level 3** | **Total** |
| **Assets** | | | | |
| Common Stocks‡ | $1307341857 | $– | $– | $1307341857 |
| Money Market Fund | 585096 | – | – | 585096 |
| Total | $1307926953 | $– | $– | $1307926953 |

---

‡ Please
 refer to the Schedule of Investments to view securities segregated by industry type.

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** ARK ETF Trust

- **b. Investment Company Act file number:** 811-22883

- **c. CIK number of Registrant:** 0001579982

- **d. LEI of Registrant:** 2549000Z0EWMH3U0CQ16

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 200 Central Avenue

  - **City:** St. Petersburg

  - **State:** FL

  - **Foreign country:** US

  - **Zip / Postal Code:** 33701

  - **Telephone number:** 727-810-8160

**Item A.2. Information about the Series.**

- **a. Name of Series:** ARK Genomic Revolution ETF

- **b. EDGAR series identifier (if any):** S000042975

- **c. LEI of Series:** 254900EYF7TANB19PE71

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-07-31

- **b. Date as of which information is reported:** 2025-10-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $1311978296.32

**Total Liabilities:** $928678.50

**Net Assets:** $1311049617.82

**Cash Not Reported:** $3862.52

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000133119 | 3.61%                | 12.42%               | 12.03%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $-5444727.16             | $42005871.65                               |
| Month 2  | $-5372877.93             | $128381466.46                              |
| Month 3  | $18144726.16             | $113685840.24                              |

### Schedule of Portfolio Investments

| Name                                                     | Title                                                    | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Prime Medicine Inc                                       | Prime Medicine Inc                                       | CUSIP: 74168J101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   5015204 | NS      | $24775107.76  | 1.89%             |  |  |  | No            |                  1 | On Loan: No      |
| Illumina Inc                                             | Illumina Inc                                             | CUSIP: 452327109<br>LEI: SQ95QG8SR5Q56LSNF682 | Long             | EC               | CORP              | US        |    393513 | NS      | $48614596.02  | 3.71%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals Inc                            | Regeneron Pharmaceuticals Inc                            | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |     12260 | NS      | $7991068.00   | 0.61%             |  |  |  | No            |                  1 | On Loan: No      |
| Absci Corp                                               | Absci Corp                                               | CUSIP: 00091E109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |  11652929 | NS      | $49874536.12  | 3.80%             |  |  |  | No            |                  1 | On Loan: No      |
| Veracyte Inc                                             | Veracyte Inc                                             | CUSIP: 92337F107<br>LEI: 529900ESWZRHXOW27Z37 | Long             | EC               | CORP              | US        |   1132313 | NS      | $40853853.04  | 3.12%             |  |  |  | No            |                  1 | On Loan: No      |
| Incyte Corp                                              | Incyte Corp                                              | CUSIP: 45337C102<br>LEI: 549300Z4WN6JVZ3T4680 | Long             | EC               | CORP              | US        |    149878 | NS      | $14010595.44  | 1.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Adaptive Biotechnologies Corp                            | Adaptive Biotechnologies Corp                            | CUSIP: 00650F109<br>LEI: 549300ZTF7OT1FW66Q96 | Long             | EC               | CORP              | US        |   2823807 | NS      | $49021289.52  | 3.74%             |  |  |  | No            |                  1 | On Loan: No      |
| Natera Inc                                               | Natera Inc                                               | CUSIP: 632307104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    278278 | NS      | $55357842.54  | 4.22%             |  |  |  | No            |                  1 | On Loan: No      |
| Nurix Therapeutics Inc                                   | Nurix Therapeutics Inc                                   | CUSIP: 67080M103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1535169 | NS      | $19865086.86  | 1.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcturus Therapeutics Holdings                           | Arcturus Therapeutics Holdings Inc                       | CUSIP: 03969T109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   2451103 | NS      | $24437496.91  | 1.86%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                                                | Amgen Inc                                                | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |     48114 | NS      | $14358661.02  | 1.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Goldman Sachs Financial Square Treasury Obligations Fund | Goldman Sachs Financial Square Treasury Obligations Fund | CUSIP: 38141W323<br>LEI: 549300C0TCI4VJPGCS21 | Long             | STIV             | RF                | US        |    585096 | NS      | $585096.48    | 0.04%             |  |  |  | No            |                  1 | On Loan: No      |
| Quantum-Si Inc                                           | Quantum-Si Inc                                           | CUSIP: 74765K105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   7053998 | NS      | $15166095.70  | 1.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Schrodinger Inc/United States                            | Schrodinger Inc/United States                            | CUSIP: 80810D103<br>LEI: 984500044BAE4791E559 | Long             | EC               | CORP              | US        |   1916963 | NS      | $40332901.52  | 3.08%             |  |  |  | No            |                  1 | On Loan: No      |
| CareDx Inc                                               | CareDx Inc                                               | CUSIP: 14167L103<br>LEI: 549300NQOFKL9NON0U06 | Long             | EC               | CORP              | US        |   2139462 | NS      | $32091930.00  | 2.45%             |  |  |  | No            |                  1 | On Loan: No      |
| Ionis Pharmaceuticals Inc                                | Ionis Pharmaceuticals Inc                                | CUSIP: 462222100<br>LEI: 549300SI4ZGLG0BLUZ92 | Long             | EC               | CORP              | US        |    614488 | NS      | $45656458.40  | 3.48%             |  |  |  | No            |                  1 | On Loan: No      |
| Compass Pathways Plc                                     | Compass Pathways Plc                                     | CUSIP: 20451W101<br>LEI: 213800N7CUZIC6QSTZ31 | Long             | EC               | CORP              | GB        |   2157864 | NS      | $13637700.48  | 1.04%             |  |  |  | No            |                  1 | On Loan: No      |
| Veeva Systems Inc                                        | Veeva Systems Inc                                        | CUSIP: 922475108<br>LEI: 549300YZEXPDB92M2F02 | Long             | EC               | CORP              | US        |     41188 | NS      | $11993945.60  | 0.91%             |  |  |  | No            |                  1 | On Loan: No      |
| Beam Therapeutics Inc                                    | Beam Therapeutics Inc                                    | CUSIP: 07373V105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1977658 | NS      | $49461226.58  | 3.77%             |  |  |  | No            |                  1 | On Loan: No      |
| Guardant Health Inc                                      | Guardant Health Inc                                      | CUSIP: 40131M109<br>LEI: 254900M8C3E5VC8BR186 | Long             | EC               | CORP              | US        |    693573 | NS      | $64516160.46  | 4.92%             |  |  |  | No            |                  1 | On Loan: No      |
| Twist Bioscience Corp                                    | Twist Bioscience Corp                                    | CUSIP: 90184D100<br>LEI: 549300T23BL59LCOH584 | Long             | EC               | CORP              | US        |   2107045 | NS      | $69300710.05  | 5.29%             |  |  |  | No            |                  1 | On Loan: No      |
| 10X Genomics Inc                                         | 10X Genomics Inc                                         | CUSIP: 88025U109<br>LEI: 5493003Z6741WNLG7H43 | Long             | EC               | CORP              | US        |   3273458 | NS      | $44649967.12  | 3.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Standard BioTools Inc                                    | Standard BioTools Inc                                    | CUSIP: 34385P108<br>LEI: 549300GX8Y96GSB6YP89 | Long             | EC               | CORP              | US        |   3081891 | NS      | $3698269.20   | 0.28%             |  |  |  | No            |                  1 | On Loan: No      |
| Pacific Biosciences of Califor                           | Pacific Biosciences of California Inc                    | CUSIP: 69404D108<br>LEI: 529900F1BWRE1M0KZN89 | Long             | EC               | CORP              | US        |  10912676 | NS      | $25535661.84  | 1.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Caris Life Sciences Inc                                  | Caris Life Sciences Inc                                  | CUSIP: 142152107<br>LEI: 549300LX5LO78M5VPY43 | Long             | EC               | CORP              | US        |    247983 | NS      | $7459328.64   | 0.57%             |  |  |  | No            |                  1 | On Loan: No      |
| 908 Devices Inc                                          | 908 Devices Inc                                          | CUSIP: 65443P102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1987967 | NS      | $15863976.66  | 1.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Personalis Inc                                           | Personalis Inc                                           | CUSIP: 71535D106<br>LEI: 549300EZ2NYFK7H0US48 | Long             | EC               | CORP              | US        |   7932773 | NS      | $76471931.72  | 5.83%             |  |  |  | No            |                  1 | On Loan: No      |
| GeneDx Holdings Corp                                     | GeneDx Holdings Corp                                     | CUSIP: 81663L200<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    104522 | NS      | $14310107.02  | 1.09%             |  |  |  | No            |                  1 | On Loan: No      |
| ATAI Life Sciences NV                                    | ATAI Life Sciences NV                                    | CUSIP: 000000000<br>LEI: 391200Z8UWPJSNBNCA11 | Long             | EC               | CORP              | DE        |   3040124 | NS      | $17754324.16  | 1.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Cerus Corp                                               | Cerus Corp                                               | CUSIP: 157085101<br>LEI: 254900BIEY9XIDA04Q21 | Long             | EC               | CORP              | US        |   6731213 | NS      | $9894883.11   | 0.75%             |  |  |  | No            |                  1 | On Loan: No      |
| Recursion Pharmaceuticals Inc                            | Recursion Pharmaceuticals Inc                            | CUSIP: 75629V104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |  11438284 | NS      | $63139327.68  | 4.82%             |  |  |  | No            |                  1 | On Loan: No      |
| CRISPR Therapeutics AG                                   | CRISPR Therapeutics AG                                   | CUSIP: 000000000<br>LEI: 506700O6IRRIQLT3W370 | Long             | EC               | CORP              | CH        |   1793364 | NS      | $114757362.36 | 8.75%             |  |  |  | No            |                  1 | On Loan: No      |
| Tempus AI Inc                                            | Tempus AI Inc                                            | CUSIP: 88023B103<br>LEI: 2549009LA0KWRAGQBX50 | Long             | EC               | CORP              | US        |   1485368 | NS      | $133460314.80 | 10.18%            |  |  |  | No            |                  1 | On Loan: No      |
| Intellia Therapeutics Inc                                | Intellia Therapeutics Inc                                | CUSIP: 45826J105<br>LEI: 5493002T5BCPE5DZC723 | Long             | EC               | CORP              | US        |   3095606 | NS      | $39066547.72  | 2.98%             |  |  |  | No            |                  1 | On Loan: No      |
| Exact Sciences Corp                                      | Exact Sciences Corp                                      | CUSIP: 30063P105<br>LEI: 549300VM3X1FYD4N9Z14 | Long             | EC               | CORP              | US        |    340042 | NS      | $21997316.98  | 1.68%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Inc                               | Vertex Pharmaceuticals Inc                               | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |     26103 | NS      | $11108653.71  | 0.85%             |  |  |  | No            |                  1 | On Loan: No      |
| Butterfly Network Inc                                    | Butterfly Network Inc                                    | CUSIP: 124155102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   6266402 | NS      | $16856621.38  | 1.29%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2025-12-22

**Name of Applicant:** ARK ETF Trust

**Signature:** Bill Cox

**Name of Signer:** Bill Cox

**Title:** Principal Financial Officer